Categories
Archives
Receive Email Updates
-
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Category Archives: Patent Eligible Subject Matter
CardioNet v. Infobionics: The Requirement for Improvements in Patent Eligibility
This decision, Appeal No. 2019-1149 (Fed. Cir. April 17th 2020) should have required about 13 pages and could have ended after the first paragraph under Section A. Instead, a split panel required a 23 page majority decision and a 10 … Continue reading
Solicitor General’s Vanda Brief Deconstructs Mayo
When I was writing my post on INO Therapeutic’s Petition for Cert. on March 16th, I noticed the cite to the “invitation brief in Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals Inc., No. 18-817 (U.S. Dec. 6, 2019)(“the brief”). While … Continue reading
Illumina v. Ariosa – The “Bucket” to Be In
Today, a divided Fed. Cir. panel reversed the district court’s decision invalidating the claim of two Illumina patents, U.S. Pat. Nos. 9,580,751 and 9,738,931, as directed to a natural phenomenon (Illumina, Inc. v. Ariosa Diagnostics, Inc., Appeal No. 2019-1419 (Fed. … Continue reading
INO v. Praxair – Time for the Supreme Court to Step Up to the Plate?
Before you read this post, please back up and read my post of September 3, 2019 which discusses the Fed. Cir.’s ruling that the claims of U.S. Pat. No. 8,794,742 are patent-ineligible as attempts to claim a natural phenomenon. The … Continue reading